Literature DB >> 11280719

Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication.

M M Saunders1, M J Seraj, Z Li, Z Zhou, C R Winter, D R Welch, H J Donahue.   

Abstract

Breast cancer progresses toward increasingly malignant behavior in tumorigenic and metastatic stages. In the series of events in the metastatic stage, tumor cells leave the primary tumor in breast and travel to distant sites where they establish secondary tumors, or metastases. In this report, we demonstrate that cell-cell communication via gap junctions is restored in the metastatic human breast carcinoma cell line MDA-MB-435 when it is transfected with breast metastasis suppressor 1 (BRMS1) cDNA. Furthermore, the expression profile of connexins (Cxs), the protein subunits of gap junctions, changes. Specifically, the expression of BRMS1 in MDA-MB-435 cells increases Cx43 expression and reduces Cx32 expression, resulting in a gap junction phenotype more similar to normal breast tissue. Taken together, these results suggest that gap junctional communication and the Cx expression profile may contribute to the metastatic potential of these breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11280719

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  82 in total

1.  Analysis of mechanisms underlying BRMS1 suppression of metastasis.

Authors:  R S Samant; M J Seraj; M M Saunders; T S Sakamaki; L A Shevde; J F Harms; T O Leonard; S F Goldberg; L Budgeon; W J Meehan; C R Winter; N D Christensen; M F Verderame; H J Donahue; D R Welch
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  BRMS1 transcriptional repression correlates with CpG island methylation and advanced pathological stage in non-small cell lung cancer.

Authors:  Alykhan S Nagji; Yuan Liu; Edward B Stelow; George J Stukenborg; David R Jones
Journal:  J Pathol       Date:  2010-06       Impact factor: 7.996

Review 3.  The epigenetics of breast cancer.

Authors:  Jovana Jovanovic; Jo Anders Rønneberg; Jörg Tost; Vessela Kristensen
Journal:  Mol Oncol       Date:  2010-04-29       Impact factor: 6.603

4.  Imaging of epidermal growth factor receptor on single breast cancer cells using surface-enhanced Raman spectroscopy.

Authors:  Lifu Xiao; Sitaram Harihar; Danny R Welch; Anhong Zhou
Journal:  Anal Chim Acta       Date:  2014-06-21       Impact factor: 6.558

Review 5.  Translational approaches using metastasis suppressor genes.

Authors:  Diane Palmieri; Christine E Horak; Jong-Heun Lee; Douglas O Halverson; Patricia S Steeg
Journal:  J Bioenerg Biomembr       Date:  2006-08       Impact factor: 2.945

6.  Cancer interaction with the bone microenvironment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section.

Authors:  Michael L Cher; Dwight A Towler; Shahin Rafii; David Rowley; Henry J Donahue; Evan Keller; Meenhard Herlyn; Eun Ah Cho; Leland W K Chung
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

7.  Bioelectric Control of Metastasis in Solid Tumors.

Authors:  Samantha L Payne; Michael Levin; Madeleine J Oudin
Journal:  Bioelectricity       Date:  2019-09-16

8.  Over-expression of the BRMS1 family member SUDS3 does not suppress metastasis of human cancer cells.

Authors:  Alexandra C Silveira; Douglas R Hurst; Kedar S Vaidya; Donald E Ayer; Danny R Welch
Journal:  Cancer Lett       Date:  2008-12-13       Impact factor: 8.679

Review 9.  The role of altered cell-cell communication in melanoma progression.

Authors:  Nikolas K Haass; Keiran S M Smalley; Meenhard Herlyn
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

10.  Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer.

Authors:  Brandon J Metge; Andra R Frost; Judy A King; Donna Lynn Dyess; Danny R Welch; Rajeev S Samant; Lalita A Shevde
Journal:  Clin Exp Metastasis       Date:  2008-06-20       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.